237 related articles for article (PubMed ID: 19780258)
41. Efficacy of epoetin alfa in a retrospective non-stratified subgroup analysis of a breast cancer cohort receiving non-platinum chemotherapy.
Bajetta E; Vercammen E; Reinhardt U; Janmohamed R; da Costa RM; Matulonis U; Guastalla JP;
Tumori; 2004; 90(5):449-57. PubMed ID: 15656327
[TBL] [Abstract][Full Text] [Related]
42. A new induction schedule of epoetin alfa 40.000 IU in anemic patients with advanced lung cancer.
Ariganello O; Mancuso A; Di Molfetta M; Diana F; Beccaglia P; Cortesi E; De Marinis F
Lung Cancer; 2004 Oct; 46(1):119-24. PubMed ID: 15364140
[TBL] [Abstract][Full Text] [Related]
43. Once-weekly epoetin alfa dosing is as effective as three times-weekly dosing in increasing hemoglobin levels and is associated with improved quality of life in anemic HIV-infected patients.
Grossman HA; Goon B; Bowers P; Leitz G;
J Acquir Immune Defic Syndr; 2003 Dec; 34(4):368-78. PubMed ID: 14615654
[TBL] [Abstract][Full Text] [Related]
44. Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial.
Pronzato P; Cortesi E; van der Rijt CC; Bols A; Moreno-Nogueira JA; de Oliveira CF; Barrett-Lee P; Ostler PJ; Rosso R;
Oncologist; 2010; 15(9):935-43. PubMed ID: 20798194
[TBL] [Abstract][Full Text] [Related]
45. Clinical benefits of once-weekly epoetin alfa in anemic patients with colorectal cancer receiving chemotherapy.
Chu E; Einhorn LH; Lefebvre P
J Support Oncol; 2006 May; 4(5):243-50. PubMed ID: 16724648
[TBL] [Abstract][Full Text] [Related]
46. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population.
Cella D; Zagari MJ; Vandoros C; Gagnon DD; Hurtz HJ; Nortier JW
J Clin Oncol; 2003 Jan; 21(2):366-73. PubMed ID: 12525531
[TBL] [Abstract][Full Text] [Related]
47. Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin alpha in anemic cancer patients receiving platinum-based chemotherapy.
Granetto C; Ricci S; Martoni A; Pezzella G; Testore F; Mattioli R; Lampignano M; Tacconi F; Porrozzi S; Gasparini G; Mantovani G;
Oncol Rep; 2003; 10(5):1289-96. PubMed ID: 12883695
[TBL] [Abstract][Full Text] [Related]
48. A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy: an open-label, non randomized, pilot study.
Santini D; Vincenzi B; La Cesa A; Virzi V; Navajas F; Malafarina V; Dicuonzo G; Cassandro R; Esposito V; Montesarchio V; Groeger AM; Tonini G
Anticancer Res; 2005; 25(1B):669-74. PubMed ID: 15816644
[TBL] [Abstract][Full Text] [Related]
49. Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy.
O'Shaughnessy JA; Vukelja SJ; Holmes FA; Savin M; Jones M; Royall D; George M; Von Hoff D
Clin Breast Cancer; 2005 Feb; 5(6):439-46. PubMed ID: 15748464
[TBL] [Abstract][Full Text] [Related]
50. Once-weekly epoetin-beta improves hemoglobin levels in cancer patients with chemotherapy-induced anemia: A randomized, double-blind, dose-finding study.
Morishima Y; Ogura M; Yoneda S; Sakai H; Tobinai K; Nishiwaki Y; Minami H; Hotta T; Ezaki K; Ohe Y; Yokoyama A; Tsuboi M; Mori K; Watanabe K; Ohashi Y; Hirashima K; Saijo N;
Jpn J Clin Oncol; 2006 Oct; 36(10):655-61. PubMed ID: 16987908
[TBL] [Abstract][Full Text] [Related]
51. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy.
Henry DH; Dahl NV; Auerbach M; Tchekmedyian S; Laufman LR
Oncologist; 2007 Feb; 12(2):231-42. PubMed ID: 17296819
[TBL] [Abstract][Full Text] [Related]
52. An induction dose of epoetin alpha of 40 000 IU daily for three consecutive days increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
Mustacchi G; Ceccherini R; Dellach C; Foladore S; Milani S; Leita M; Sisto M
Ann Oncol; 2006 Nov; 17(11):1705-8. PubMed ID: 16980603
[TBL] [Abstract][Full Text] [Related]
53. Predicting the hematopoietic response to recombinant human erythropoietin (Epoetin alfa) in the treatment of the anemia of cancer.
Adamson JW; Ludwig H
Oncology; 1999; 56(1):46-53. PubMed ID: 9885377
[TBL] [Abstract][Full Text] [Related]
54. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.
Demetri GD; Kris M; Wade J; Degos L; Cella D
J Clin Oncol; 1998 Oct; 16(10):3412-25. PubMed ID: 9779721
[TBL] [Abstract][Full Text] [Related]
55. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice.
Patton J; Reeves T; Wallace J
Oncologist; 2004; 9(4):451-8. PubMed ID: 15266098
[TBL] [Abstract][Full Text] [Related]
56. Anemia of cancer patients: patient selection and patient stratification for epoetin treatment.
Ludwig H; Fritz E
Semin Oncol; 1998 Jun; 25(3 Suppl 7):35-8. PubMed ID: 9671328
[TBL] [Abstract][Full Text] [Related]
57. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.
Provenzano R; Bhaduri S; Singh AK;
Clin Nephrol; 2005 Aug; 64(2):113-23. PubMed ID: 16114787
[TBL] [Abstract][Full Text] [Related]
58. Prior red blood cell transfusions in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management.
Couture F; Turner AR; Melosky B; Xiu L; Plante RK; Lau CY; Quirt I
Oncologist; 2005 Jan; 10(1):63-71. PubMed ID: 15632253
[TBL] [Abstract][Full Text] [Related]
59. Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia? Summary of trials of cancer, HIV/AIDS, and chronic kidney disease.
Kimel M; Leidy NK; Mannix S; Dixon J
Value Health; 2008; 11(1):57-75. PubMed ID: 18237361
[TBL] [Abstract][Full Text] [Related]
60. Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial.
Savonije JH; van Groeningen CJ; van Bochove A; Honkoop AH; van Felius CL; Wormhoudt LW; Giaccone G
Eur J Cancer; 2005 Jul; 41(11):1560-9. PubMed ID: 15953714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
